girentuximab

Home
Ligands
girentuximab

GtoPdb Ligand ID: 7987

Synonyms: cG250 | G250 | Rencarex® (proposed proprietary name) | WX-G250

Comment: Girentuximab is a monoclonal antibody directed against carbonic anhydrase 9 (CA9) [5].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.

References
1. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S et al.. (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer, 90 (5): 985-90. [PMID:14997194]
2. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY et al.. (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res, 9 (2): 802-11. [PMID:12576453]
3. Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA et al.. (2007) A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun, 7: 13. [PMID:17705349]
4. Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, Grisanzio C, Signoretti S. (2010) Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol, 134 (6): 873-9. [PMID:21088149]
5. Zatovicova M, Jelenska L, Hulikova A, Ditte P, Ditte Z, Csaderova L, Svastova E, Schmalix W, Boettger V, Bevan P et al.. (2014) Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model. Int J Oncol, 45 (6): 2455-67. [PMID:25230982]

References

1. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S et al.. (2004)
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.
Br J Cancer, 90 (5): 985-90. [PMID:14997194]

2. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY et al.. (2003)
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Clin Cancer Res, 9 (2): 802-11. [PMID:12576453]

3. Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA et al.. (2007)
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
Cancer Immun, 7: 13. [PMID:17705349]

4. Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, Grisanzio C, Signoretti S. (2010)
Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.
Am J Clin Pathol, 134 (6): 873-9. [PMID:21088149]

5. Zatovicova M, Jelenska L, Hulikova A, Ditte P, Ditte Z, Csaderova L, Svastova E, Schmalix W, Boettger V, Bevan P et al.. (2014)
Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Int J Oncol, 45 (6): 2455-67. [PMID:25230982]